Evaluation of Quality of Life on Functional, Symptoms, and Global Health Status in Breast Cancer Patients among Chemotherapy Cycles with Cyclophosphamide-Doxorubicin-5Fluorouracil
Abstract
Treatment of breast cancer with chemotherapy in several cycles has led to differences in patients' quality of life. One of the chemotherapy recommendations for breast cancer is Cyclophosphamide-Doxorubicin-5Fluorouracil (CAF). Therefore, this research aimed to determine the quality of life among chemotherapy cycles with CAF in breast cancer patients at Dr. Zainoel Abidin Hospital Banda Aceh. This is an observational analytic study with the cross-sectional method, where 32 patients were obtained through a total sampling technique from June to August 2019. Quality of life was measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C-30), while the Kruskal-Wallis test performed the statistical analysis. The results showed that the quality of life of breast cancer patients has no significant difference among chemotherapy cycles with CAF (p>0,05). However, some changes in the functional and symptom scale among patients required a further follow-up by healthcare professionals to improve the quality of life.
Keywords: CAF, cycle, QLQ C-30, quality of life
Evaluasi Kualitas Hidup pada Status Fungsional, Gejala, dan Kesehatan Umum pada Pasien Kanker Payudara Antarsiklus Kemoterapi dengan Cyclophosphamide-Doxorubicin-5Fluorouracil
Abstrak
Penggunaan kemoterapi dalam beberapa siklus sebagai pengobatan kanker payudara dapat menimbulkan perbedaan kualitas hidup pasien. Salah satu kemoterapi yang direkomendasikan untuk kanker payudara adalah Cyclophosphamide-Doxorubicin-5Fluorouracil (CAF). Tujuan penelitian ini adalah mengetahui perbedaan kualitas hidup pasien kanker payudara antarsiklus dengan kemoterapi CAF di Rumah Sakit Umum Daerah dr. Zainoel Abidin Banda Aceh. Jenis penelitian ini adalah observasional analitik dengan metode cross-sectional. Sampel berjumlah 32 pasien yang diperoleh menggunakan teknik total sampling dari bulan Juni sampai Agustus 2019. Penilaian kualitas hidup dilakukan menggunakan European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C-30) dan analisis statistik menggunakan uji Kruskall-Wallis. Hasil penelitian menunjukkan bahwa tidak terdapat perbedaan kualitas hidup yang signifikan antarsiklus pada pasien kanker payudara dengan kemoterapi CAF (p>0,05). Meskipun demikian, beberapa perubahan skala fungsional dan gejala yang dirasakan pasien pada tiap siklus kemoterapi yang dihadapi perlu menjadi perhatian bagi tenaga kesehatan dalam rangka meningkatkan kualitas hidup pasien.
Kata kunci: CAF, kualitas hidup, siklus , QLQ C-30
Keywords
Full Text:
PDFReferences
WHO International Agency for Research on Cancer. Indonesia [Accessed on: June 2019]. Available at: http://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf
WHO International Agency for Research on Cancer. New global cancer data [Accessed on: June 2019]. Available at: https://www.uicc.org/new-global-cancer-data-globocan-2018
Sugerman DT. Chemotherapy. J Am Med Assoc 2013;310(2):218. doi: 10.1001/jama.2013.5525
Fisusi AF, Emmanuel OK. Drug combinations in breast cancer therapy. Pharm Nanotechnol. 2019;7(1):3–23. doi: 10.2174/2211738507666190122111224
World Health Organization. Guidelines for management of breast cancer [Accessed on: April 1, 2019]. Available at: http://applications.emro.who.int/dsaf/dsa697.pdf
Manuaba TW. Panduan penatalaksanaan kanker solid PERABOI. Jakarta: Sagung Seto; 2010.
Kementerian Kesehatan Republik Indonesia. Panduan penatalaksanaan kanker payudara [Accessed on: March 1, 2019]. Available at:
http://kanker.kemkes.go.id/guidelines/PPKPayudara.pdf
Abdollahzadeh F, Aghahossini SS, Rahmani A, Kermani IA. Quality of life in cancer patients and its related factors. J Caring Sci. 2012;1(2):109–14.
King S, Exley J, Parks S, Ball S, Bienkowska-Gibbs T, MacLure C. The use and impact of quality of life assessment tools in clinical care settings for cancer patients, with a particular emphasis on brain cancer: Insights from a systematic review and stakeholder consultations. Qual Life Res. 2016;25(9):2245–56. doi: 10.1007/s11136-016-1278-6
Zhu J, Liu R, Jiang Z, Wang P, Yau Y, Shen Z. Optimization of drug regimen in chemotherapy based on semi-mechanistic model for myelosuppression. J Biomed Inform. 2015;57:20–7. doi: 10.1016/j.jbi.2015.06.021
Paraskevi T. Quality of life outcomes in patients with breast cancer. Oncol Rev. 2012;6(1):e2. doi: 10.4081/oncol.2012.e2
Damodar G, Smitha T, Gopinatha S, Vijayakumar S, Yedukondala AR. Assessment of quality of life in breast cancer patients at a tertiary care hospital. Arch Pharm Pract. 2013;4(1):15–20.
Agustini DD, Surahman E, Abdulah R. Kualitas hidup pasien kanker payudara dengan terapi kombinasi fluorouracil, doxorubicin, dan cyclofosfamide. Indones J Clin Pharm. 2015;4(3):175–85. doi: 10.15416/ijcp.2015.4.3.175
Perwitasari DA, Atthobari J, Dwiprahasto I, Hakimi M, Galderblom H, Putter H, et al. Translation and validation of EORTC QLQ-C30 into Indonesian version for cancer patients in Indonesia. Jpn J Clin Oncol. 2011;41(4):519–29. doi: 10.1093/jjco/hyq243
Conley CC, Bishop BT, Andersen BL. Emotions and emotion regulation in breast cancer survivorship. Healthcare (Basel). 2016;4(3):56. doi: 10.3390/healthcare4030056
Muniyandi DK, Ganesan RM, Meenakshisundaram M, Palanichamu S. Effect of cancer chemotherapy on cognitive function. Int J Cancer Res. 2018;14(2):52–7. doi: 10.3923/ijcr.2018.52.57
Javeed K, Reddy V, Forshing L. Neuroanatomy, cerebral cortex [Accessed on: August 2019]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK537247/
Manir KS, Bhadra K, Kumar G, Manna A, Patra NB, Sarkar SK. Fatigue in breast cancer patients on adjuvant treatment: Course and prevalence. Indian J Palliat Care. 2012;18(2):109–16. doi: 10.4103/0973-1075.100826
Tabrizi FM, Alizadeh S. Cancer related fatigue in breast cancer survivors: In correlation to demographic factors. Maedica (Bucur). 2017;12(2):106–11.
British Columbia Cancer Agency. Cancer drug manual: Cyclophosphamide [Accessed on: April 2019]. Available at: http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Cyclophosphamide_monograph_1June2013_formatted.pdf
British Columbia Cancer Agency. Cancer drug manual: Doxorubicin [Accessed on: April 2019]. Available at: http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Doxorubicin_monograph.pdf
British Columbia Cancer Agency. Cancer drug manual: Fluorouracil [Accessed on: April 2019]. Available at: http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Fluorouracil_monograph.pdf
Pourali L, Taghizadeh A, Akhoundi MR, Varshoei F, Zarifian A, Andalibi MSS. Frequency of chemotherapy induced anemia in breast cancer patients. Int J Cancer Manag. 2017;10(1):e4672. doi: 10.17795/ijcp-4672
Rodgers GM, Becker PS, Blinder M, Cella D, Chanan-Khan, A, Cleeland C, et al. Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw. 2012;10(5):628–53.
Trill MD. Anxiety and sleep disorders in cancer patients. Eur J Cancer Suppl. 2013;11(2):216–24. doi: 10.1016/j.ejcsup.2013.07.009
Oh CM, Kim HY, Na HK, Cho KH, Chu MK. The effect of anxiety and depression on sleep quality of individuals with high risk for insomnia: A population-based study. Front Neurol. 2019;10:849. doi: 10.3389/fneur.2019.00849
Marinho EdC, Custodo IDD, Ferreira IB, Crispim CA, Paiva CE, Maia YCdP. Impact of chemotherapy on perceptions related to food intake in women with breast cancer: A prospective study. PLoS One. 2017;12(11):e0187573. doi: 10.1371/journal.pone.0187573.
Muscaritoli M, Lucia S, Farcomeni A, Lorusso V, Saracino V, Barone C, et al. Prevalence of malnutrition in patients at first medical oncology visit: The PreMiO study. Oncotarget. 2017;8(45):79884-96. doi: 10.18632/oncotarget.20168
Cooper C, Burden ST, Cheng H, Molassiotis A. Understanding and managing cancer-related weight loss and anorexia: insights from a systematic review of qualitative research. J Cachexia Sarcopenia Muscle. 2015;6(1):99–111. doi: 10.1002/jcsm.12010
McQuade RM, Stojanovska V, Abalo R, Bornstein JC, Nurgali K. Chemotherapy-induced constipation and diarrhea: Pathophysiology, current and emerging treatments. Front Pharmacol. 2016;7:414. doi: 10.3389/fphar.2016.00414
Wickham RJ. Managing constipation in adults with cancer. J Adv Pract Oncol. 2017;8(2):149–61.
Chaturvedi SK, Muliyala KP. The meaning in quality of life. J Psychosoc Rehabilitation Ment Health. 2016;3(2):47–9. 10.1007/s40737-016-0069-2
Cherchiglia ML. Moreira DP, Simino GP. Quality of life of patients with cancer undergoing chemotherapy in Belo Horizonte Hospitals. Value Health 2018;21(1):S39. doi: 10.1016/j.jval.2018.04.321
Juwita AD, Almahdy, Afdhila R. Pengaruh karakteristik pasien terhadap kualitas hidup terkait kesehatan pada pasien kanker payudara di RSUP Dr.M. Djamil Padang, Indonesia. J Sains Farmasi Klinis. 2018;5(2):126–33. doi: 10.25077/jsfk.5.2.126-133.2018
Heydarnajed MS, Hassanpour, Solati DK. Factors affecting quality of life in cancer patients undergoing chemotherapy. Afr Health Sci. 2011;11(2):266–70.
Hassen AM, Taye G, Gizaw M, Hussien FM. Quality of life and associated factors among patients with breast cancer under chemotherapy at Tikur Anbessa specialized hospital, Addis Ababa, Ethiopia. PLoS One. 2019;14(9):e0222629. doi: 10.1371/journal.pone.0222629
Nørgaard M, Ehrenstein V, Vandenbroucke JP. Confounding in observational studies based on large health care databases: Problems and potential solutions-a primer for the clinician. Clin Epidemiol. 2017;9:185–93. doi: 10.2147/CLEP.S129879
Cocks K, Madeleine KM, Galina V, Marissa MM, Peter M, Julia MB. Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol. 2011;29(1):89–96. doi: 10.1200/JCO.2010.28.0107
DOI: https://doi.org/10.15416/ijcp.2021.10.4.261
Refbacks
- There are currently no refbacks.
Indonesian Journal of Clinical Pharmacy is indexed by
